Novel small molecule activators of the NLRP3 inflammasome as immunostimulants

Funder	European Commission
Recipient Organization	Universitaetsklinikum Freiburg
Country	Germany
Start Date	Sep 01, 2021
End Date	Feb 28, 2023
Duration	545 days
Number of Grantees	1
Roles	Coordinator
Data Source	European Commission
Grant ID	`966687`

Grant Description

We have identified a novel family of potent small molecule activators of the NLRP3 inflammasome.

The goal of this project is to determine the feasibility of developing these new immunostimulators into an attractive commercial proposition.

Establishment of technical feasibility will involve identification the most promising modifications of our drug candidates and testing their efficacy in disease models of cancer and immunization.

In addition, we will determine commercial feasibility by conducting market research and competition analysis and by engaging potential industry partners.